【摘要】 目的:评价紫杉醇联合铂类药物对晚期非小细胞肺癌的客观疗效及毒副作用。方法:经病理学证实的晚期非小细胞肺癌40例,采用紫杉醇175mg/m2静脉滴注,第1天,顺铂60mg/m2~80mg/m2,第1天~第3天或卡铂(AUC=5)静脉滴注,第1天,每3周重复,所有患者均接受2周期以上的化疗。结果:可评价疗效的30例,有13例达到PR,有1例达到CR,有效率为46.7%。主要毒副作用为骨髓抑制、恶心呕吐、关节肌肉痛、肝功能损害等。大部分患者为I度、II度反应,患者耐受良好。结论:紫杉醇联合铂类方案是一种对晚期非小细胞肺癌有效的治疗方案,毒副作用轻,临床使用安全,值得临床进一步研究应用。更多还原

【Abstract】 Objective: To evaluate the objective anti-tumor efficacy and safety of the combination of Paclitaxel (Taiji Group) with cisplatin or carboplatin for the advanced non-small cell lung cancer. Methods: A total of 40 cases of advanced non-small cell lung cancer were involved. Paclitaxel was given at a dose of 175 mg·m-2(3-h intravenous infusion) in d1, followed by other cisplatin at a dose of 80 mg/m2 or carboplatin at an AUC of 5 in d1 and d2, all repeated every 3 weeks. All the patients received at least 2 cycles of the treatment. Result: In the 30 evaluable cases, complete response(CR) and partial response were observed in 1 case and 13 cases; the objective response rate was 46.7 %. The major toxicities included nausea, vomiting, myelosuppression, arthralgia and liver function impaired. The rate of severe toxicities was generally low. These side effects was mild to moderate and well tolerated. Conclusion: The combination of Paclitaxel with cisplatin or carboplatin is active in treating patients with advanced non-small cell lung cancer, with mild to moderate side effect. Further clinical investigation should be warranted.更多还原